Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | MC3R | P41968 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30799837 | 0.88 | MMP1 (0.43) | DPP4DPP8DPP9CTSSCTSC | |
| SCHEMBL30799428 | 0.83 | GHSR (0.52) | — | |
| SCHEMBL30799746 | 0.82 | CTSC (0.53) | MMECTSCMC4RMC3RCTSL | |
| SCHEMBL30799840 | 0.79 | CTSL (0.55) | CTSCCTSL | |
| SCHEMBL5257074 | 0.76 | DPP4 (0.48) | MMESLC1A3SLC1A2SLC1A1DPP4 | |
| SCHEMBL17449974 | 0.76 | DPP4 (0.48) | MMESLC1A3SLC1A2SLC1A1DPP4 | |
| SCHEMBL30799839 | 0.76 | OPRD1 (0.51) | CTSC | |
| SCHEMBL30799945 | 0.75 | CTSL (0.51) | MMECTSL | |
| SCHEMBL2242130 | 0.74 | DPP4 (0.57) | SLC1A3SLC1A2SLC1A1DPP4DPP8 | |
| SCHEMBL2242132 | 0.74 | DPP4 (0.57) | SLC1A3SLC1A2SLC1A1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | MME 467/4885SLC1A3 3197/4885SLC1A2 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.